Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;70(2):222-33.
doi: 10.1111/j.1365-2125.2010.03695.x.

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients

Affiliations

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients

Kimie Sai et al. Br J Clin Pharmacol. 2010 Aug.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Association of UDP-glucuronosyltransferase 1A1 (UGT1A1) genetic polymorphisms *6 and *28 with reduced clearance of SN-38 and severe neutropenia in irinotecan therapy was demonstrated in Japanese cancer patients. * The detailed gene structure of CES1 has been characterized. * Possible functional SNPs in the promoter region have been reported. WHAT THIS STUDY ADDS * Association of functional CES1 gene number with AUC ratio [(SN-38 + SN-38G)/irinotecan], an in vivo index of CES activity, was observed in patients with irinotecan monotherapy. * No significant effects of major CES1 SNPs on irinotecan PK were detected. AIMS Human carboxylesterase 1 (CES1) hydrolyzes irinotecan to produce an active metabolite SN-38 in the liver. The human CES1 gene family consists of two functional genes, CES1A1 (1A1) and CES1A2 (1A2), which are located tail-to-tail on chromosome 16q13-q22.1 (CES1A2-1A1). The pseudogene CES1A3 (1A3) and a chimeric CES1A1 variant (var1A1) are also found as polymorphic isoforms of 1A2 and 1A1, respectively. In this study, roles of CES1 genotypes and major SNPs in irinotecan pharmacokinetics were investigated in Japanese cancer patients. METHODS CES1A diplotypes [combinations of haplotypes A (1A3-1A1), B (1A2-1A1), C (1A3-var1A1) and D (1A2-var1A1)] and the major SNPs (-75T>G and -30G>A in 1A1, and -816A>C in 1A2 and 1A3) were determined in 177 Japanese cancer patients. Associations of CES1 genotypes, number of functional CES1 genes (1A1, 1A2 and var1A1) and major SNPs, with the AUC ratio of (SN-38 + SN-38G)/irinotecan, a parameter of in vivo CES activity, were analyzed for 58 patients treated with irinotecan monotherapy. RESULTS The median AUC ratio of patients having three or four functional CES1 genes (diplotypes A/B, A/D or B/C, C/D, B/B and B/D; n= 35) was 1.24-fold of that in patients with two functional CES1 genes (diplotypes A/A, A/C and C/C; n= 23) [median (25th-75th percentiles): 0.31 (0.25-0.38) vs. 0.25 (0.20-0.32), P= 0.0134]. No significant effects of var1A1 and the major SNPs examined were observed. CONCLUSION This study suggests a gene-dose effect of functional CES1A genes on SN-38 formation in irinotecan-treated Japanese cancer patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Metabolic pathway of irinotecan. The prodrug irinotecan is hydrolyzed by carboxylesterase (CES) to produce an active metabolite SN-38, and subsequently detoxified by UDP-glucuronosyltransferase 1As (UGT1As) to produce an inactive metabolite SN-38 glucuronide (SN-38G). Irinotecan is also metabolized by cytochrome P450 3A4 (CYP3A4) to produce another inactive metabolite APC
Figure 2
Figure 2
CES1 gene structure and haplotypes. The regions used for haplotype determination in this study are indicated with arrows (a–f)
Figure 3
Figure 3
Association of CES1 diplotypes (A) or SNPs (B–D) with AUC ratio [(SN-38 + SN-38G)/irinotecan], an in vivo index of CES activity, in Japanese cancer patients treated with irinotecan monotherapy (n= 58). ‘CES1 gene number’ means the number of functional genes (1A1, var1A1 and 1A2). Higher AUC ratios were observed in patients with three or four functional CES1 genes than with two functional genes (P= 0.0134, Mann-Whitney test) in (A). Patients with CES2*5[CES2 1A>T (M1L)] (CES2*5) and CES2*2[CES2 100C>T (R34W)] (CES2*2) were found to have reduced CES activity in our previous study [13, 14]
Figure 4
Figure 4
Association of CES1 genotypes with SN-38 AUC/dose in UGT(−/− and +/−) patients treated with irinotecan monotherapy (n= 51). ‘CES1 gene number’ means the number of functional genes (1A1, var1A1 and 1A2). One patient with an outlying value who had ABCB1*2[2677G>T (A893S)] and *14[2677G>T (A893S) and 1345G>A 230 (E448K)] was excluded from this analysis [10]. A slightly increasing trend in SN-38 AUC(/dose) was observed depending on functional CES1 gene number. (P= 0.080, Jonckheere-Terpstra test). The patients with CES2*5[CES2 1A>T (M1L)] (CES2*5) and CES2*2[CES2 100C>T (R34W)] (CES2*2) [13, 14] are marked

References

    1. Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules. 2008;13:412–31. - PMC - PubMed
    1. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 2000;60:1189–92. - PubMed
    1. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921–6. - PubMed
    1. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43–7. - PubMed
    1. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382–8. - PubMed

Publication types

MeSH terms